119 related articles for article (PubMed ID: 8616902)
1. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs.
Price GS; Page RL; Riviere JE; Cline JM; Thrall DE
Cancer Chemother Pharmacol; 1996; 38(2):129-35. PubMed ID: 8616902
[TBL] [Abstract][Full Text] [Related]
2. Effect of whole-body hyperthermia on the pharmacokinetics and toxicity of lonidamine in dogs.
Price GS; Page RL; Riviere JE; Cline JM; Thrall DE
Int J Hyperthermia; 1995; 11(4):531-44. PubMed ID: 7594807
[TBL] [Abstract][Full Text] [Related]
3. Effect of whole-body hyperthermia on lonidamine and doxorubicin pharmacokinetics and toxicity in dogs.
Price GS; Page RL; Riviere JE; Cline JM; Frazier DL; Thrall DE
Int J Hyperthermia; 1995; 11(4):545-59. PubMed ID: 7594808
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of oral lonidamine in breast and lung cancer patients.
Newell DR; Mansi J; Hardy J; Button D; Jenns K; Smith IE; Picollo R; Catanese B
Semin Oncol; 1991 Apr; 18(2 Suppl 4):11-7. PubMed ID: 2031191
[TBL] [Abstract][Full Text] [Related]
5. Potential complications associated with normothermic lonidamine infusion and with systemic acidosis in dogs receiving lonidamine during whole body hyperthermia (WBH).
Price GS; Cline JM; Page RL; Riviere JE; Thrall DE
Int J Hyperthermia; 1998; 14(3):271-83. PubMed ID: 9679707
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and metabolism of lonidamine in rats: evidence of enterohepatic recycling.
Besner JG; Leclaire R; Roy JJ
Drug Metab Rev; 1997; 29(1-2):219-34. PubMed ID: 9187520
[No Abstract] [Full Text] [Related]
7. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer.
Mansi JL; de Graeff A; Newell DR; Glaholm J; Button D; Leach MO; Payne G; Smith IE
Br J Cancer; 1991 Sep; 64(3):593-7. PubMed ID: 1911204
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and toxicokinetics of the cyclin-dependent kinase inhibitor AG-024322 in cynomolgus monkeys following intravenous infusion.
Brown AP; Courtney CL; Criswell KA; Holliman CL; Evering W; Jessen BA
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1091-101. PubMed ID: 18509643
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Dogliotti L; Danese S; Berruti A; Zola P; Buniva T; Bottini A; Richiardi G; Moro G; Farris A; Baù MG; Porcile G
Cancer Chemother Pharmacol; 1998; 41(4):333-8. PubMed ID: 9488603
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and clinical tolerance of lonidamine.
Robustelli della Cuna G; Pedrazzoli P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):18-22. PubMed ID: 2031192
[TBL] [Abstract][Full Text] [Related]
11. Carcinogenicity assessment of lonidamine by dietary administration to Sprague-Dawley rats.
Patton DS; Heywood R; Barcellona PS
Toxicol Lett; 1992 Sep; 62(2-3):209-14. PubMed ID: 1412505
[TBL] [Abstract][Full Text] [Related]
12. Glycosyl and polyalcoholic prodrugs of lonidamine.
Giorgioni G; Ruggieri S; Di Stefano A; Sozio P; Cinque B; Di Marzio L; Santoni G; Claudi F
Bioorg Med Chem Lett; 2008 Apr; 18(7):2445-50. PubMed ID: 18321702
[TBL] [Abstract][Full Text] [Related]
13. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410
[TBL] [Abstract][Full Text] [Related]
14. Lonidamine and hyperthermia: clinical experience in melanoma. Preliminary results.
Cavaliere R; Di Filippo F; Varanese A; Carlini S; Calabro A; Aloe L; Piarulli L
Oncology; 1984; 41 Suppl 1():116-20. PubMed ID: 6717890
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of lonidamine.
Segre G; Catanese B
Chemotherapy; 1981; 27 Suppl 2():77-84. PubMed ID: 7285639
[No Abstract] [Full Text] [Related]
16. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
17. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
18. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
Teicher BA; Herman TS; Tanaka J; Dezube B; Pardee A; Frei E
Cancer Chemother Pharmacol; 1991; 28(1):45-50. PubMed ID: 1904012
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
[TBL] [Abstract][Full Text] [Related]
20. Lonidamine in high-risk breast cancer patients.
Possinger K; Wagner H; Kovacs S; Flath B; Classen S; Wilmanns W
Semin Oncol; 1991 Apr; 18(2 Suppl 4):58-61. PubMed ID: 2031199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
